Fig. 3: TCP1 inhibition affects hepatocellular carcinoma (HCC) and pancreatic ductal carcinoma (PDAC) cell functions in vivo. | Communications Biology

Fig. 3: TCP1 inhibition affects hepatocellular carcinoma (HCC) and pancreatic ductal carcinoma (PDAC) cell functions in vivo.

From: TCP1 promotes the progression of malignant tumours by stabilizing c-Myc through the AKT/GSK-3β and ERK signalling pathways

Fig. 3

Xenograft tumour and tail vein transport models were constructed with stable expression of shRNA targeting TCP1 (shTCP1). a–c Xenograft tumour models were constructed with SMMC-7721 (n = 12), Huh7 (n = 10) and PANC-1 (n = 10) cells. a Photographs of tumours collected from nude mice. b TCP1 knockdown modulated tumour volume growth in vivo. c TCP1 knockdown induced tumour weight loss in vivo (measured at the endpoint). d–f A live imaging system for small animals was used to assay the metastatic ability of HCC and PDAC cell lines in vivo. Tail vein transport models were constructed with SMMC-7721 and BxPC-3-luciferase cells harbouring TCP1 shRNA or control vector (n = 10 per group). d Photographs of tissues collected from nude mice. e The intensity of the contrast band indicated that TCP1 knockdown decreased metastasis in vivo. f Kaplan–Meier survival analysis of knockdown and control mice. The data are shown as the mean ± SD. One-way ANOVA and Student’s t-test were used; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significance.

Back to article page